Synple Chem joins US-based eMolecules

Since 2016, Synple Chem has been developing automated laboratory equipment for chemistry research, today serving customers worldwide including Novartis, AstraZeneca, Lilly and Bayer. The ETH spinoff has now been acquired by eMolecules Inc., developer of a robust and accurate digital chemical search engine for the chemical industry.

Founded by Benedikt Wanner (Founder & CEO) and Paula Nichols (Co-founder and CCO) along with their team, Synpl Chem is a pioneering Zurich-based company that specializes in automated chemical synthesis for small molecules drug discovery customers. Founded as a spin-off from ETH Zurich, it develops innovative synthesizers that streamline the molecule synthesis process. Synple Chem offers reagent cartridges for eight reaction classes, encompassing more than 40 different reagents, enabling researchers to conduct fully automated and optimized experiments.

Synple Chem serves premier pharma and biotech customers in the United States and in Europe. Among its customers are some of the world's leading pharma companies such as Novartis, Lilly, Bayer, Merck, Jansen, Sanofi, AstraZeneca among others.

The startup has been acquired by eMolecules Inc., a San Diego based company providing industry-leading chemical compound search-and-fulfilment platform for early discovery chemistry research that built the most powerful, reliable and accurate digital chemical search engine directly connecting chemists to the world's largest readily available chemical space.

"We are thrilled to welcome the highly reputable and talented Synple team into eMolecules," said Dr. Niko Gubernator, CEO and President of eMolecules. "As a combined company, we are poised to deepen and broaden our relationships with research organizations. Our customers have expressed the need for a true, global, end-to-end partner to support efficient compound procurement, management and automation across regionally distributed chemistry groups. We look forward to capitalizing on opportunities to expand our offerings and innovate for our customers."

Combining Synple's virtual compound library, which provides access to more than 7 trillion tractable compounds, with eMolecules' eXplore library of more than 4 trillion compounds, eMolecules now offers the world's most diverse selection of virtual compounds. This acquisition expands its product and service portfolio to include automation solutions and enhances its one-stop-shop solution provider for efficient chemical compound procurement, full-service compound management and automation solutions for drug discovery researchers. Researchers can quickly and efficiently search for and obtain compounds from hundreds of specialty chemical suppliers with over 100 million in-stock SKUs, while simultaneously searching across their own proprietary libraries and now also trillions of virtual compounds via eMolecules' and Synple's virtual libraries.

"We are excited to join forces with eMolecules, a company that shares our vision of revolutionizing the way researchers access chemical compounds and the chemical space," said Dr. Benedikt Wanner, CEO of Synple. "By integrating Synple's automated synthesis technology and extensive virtual compound library into eMolecules' unparalleled search-and-fulfillment platform, we are uniquely positioned to empower drug discovery teams with the tools they need to accelerate innovation and their discovery faster than ever before."

(Press release/RAN)